Last reviewed · How we verify

KM-001 cream 1% 16 weeks treatment.

Kamari Pharma Ltd · Phase 1 active Small molecule

KM-001 cream 1% 16 weeks treatment. is a Small molecule drug developed by Kamari Pharma Ltd. It is currently in Phase 1 development. Also known as: Experimental drug administration-cohort 2.

At a glance

Generic nameKM-001 cream 1% 16 weeks treatment.
Also known asExperimental drug administration-cohort 2
SponsorKamari Pharma Ltd
ModalitySmall molecule
PhasePhase 1

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about KM-001 cream 1% 16 weeks treatment.

What is KM-001 cream 1% 16 weeks treatment.?

KM-001 cream 1% 16 weeks treatment. is a Small molecule drug developed by Kamari Pharma Ltd.

Who makes KM-001 cream 1% 16 weeks treatment.?

KM-001 cream 1% 16 weeks treatment. is developed by Kamari Pharma Ltd (see full Kamari Pharma Ltd pipeline at /company/kamari-pharma-ltd).

Is KM-001 cream 1% 16 weeks treatment. also known as anything else?

KM-001 cream 1% 16 weeks treatment. is also known as Experimental drug administration-cohort 2.

What development phase is KM-001 cream 1% 16 weeks treatment. in?

KM-001 cream 1% 16 weeks treatment. is in Phase 1.

Related